Why Cardiovascular Risk Increases After Menopause

For decades, cardiovascular disease (CVD) was largely perceived as a condition affecting men. Today, the evidence tells a different story. Women's cardiovascular risk rises sharply after menopause and for healthcare professionals managing women in this life stage, understanding why is essential for timely, effective intervention. The menopausal transition is not merely a reproductive milestone; it is a significant cardiovascular inflection point. Recognising it as such enables clinicians to implement preventive strategies before risk factors escalate into serious events.

How Oestrogen Loss Affects the Heart

Oestrogen plays a protective role in cardiovascular health. It supports healthy blood vessel function, helps regulate blood pressure, and contributes to favourable lipid profiles. When oestrogen levels decline during menopause, these protective mechanisms weaken.

The consequences are measurable. Postmenopausal women tend to experience increases in LDL cholesterol, decreases in HDL cholesterol, and a rise in blood pressure - all established cardiovascular risk factors. Additionally, oestrogen loss is associated with changes in resting energy expenditure, meaning the body burns fewer calories at rest, contributing to metabolic shifts that further elevate cardiovascular risk.

This hormonal transition also increases susceptibility to irregular heart rhythms. Atrial fibrillation (AFib), already a significant stroke risk factor, becomes more prevalent in postmenopausal women making cardiac monitoring in this population particularly important.

Body Composition Changes During Menopause and Their Cardiovascular Impact

Beyond hormonal changes, the menopausal transition brings significant shifts in body composition that directly influence cardiovascular health. Women going through this transition typically experience:

• Increased fat mass, particularly visceral fat accumulation around abdominal organs

• Reduced fat-free mass, including a decline in muscle mass

• A slower metabolism, partly driven by reduced oestrogen and changes in resting energy expenditure

These are not cosmetic concerns. Visceral fat is metabolically active and strongly associated with insulin resistance, inflammation, dyslipidaemia, and hypertension all key drivers of cardiovascular disease. Unlike subcutaneous fat, visceral fat cannot be assessed simply by measuring body weight. Tracking it specifically is critical for understanding true cardiovascular risk.

Muscle mass loss compounds the problem. Reduced skeletal muscle is associated with lower metabolic rate, reduced physical capacity, and poorer glycaemic control, each of which independently contributes to cardiovascular risk.

Understanding the Scale of the Risk

The numbers are stark. Women with obesity face a four-fold increased risk of cardiovascular death compared to women of healthy weight. Given that menopause is itself associated with weight gain and visceral fat accumulation, this intersection creates a period of substantially elevated risk that must not be underestimated.

Clinicians should also be aware that cardiovascular events in women can present differently than in men - with symptoms that are less classically recognisable making proactive monitoring, rather than reactive diagnosis, all the more important.

The Role of Early Detection and Monitoring

The menopausal transition represents a critical window for cardiovascular intervention. Risk factors that emerge or worsen during this period - hypertension, dyslipidaemia, increased visceral fat, irregular heart rhythms - are modifiable if detected early. Yet they often go untracked unless patients and providers are actively looking for them.

Regular monitoring of blood pressure, heart rhythm, and body composition gives healthcare professionals the data they need to personalise risk management. It also empowers patients to engage meaningfully with their own cardiovascular health - a key factor in long-term adherence to lifestyle and treatment plans.

How OMRON's Technology Supports Women During the Menopausal Transition

OMRON offers two devices that together address the key cardiovascular risk dimensions relevant to menopausal women.

The M4 Connect AFib supports early detection of high blood pressure and irregular heart rhythms, both of which increase in prevalence and significance after menopause. Accurate, consistent blood pressure monitoring at home enables timely identification of hypertension, while AFib detection supports prompt clinical follow-up before stroke risk escalates.

The BF511 Body Composition Monitor tracks visceral fat, body fat percentage, skeletal muscle, and resting metabolism - the body composition parameters most directly affected by hormonal changes during menopause. Using 8-sensor full body technology for clinically validated accuracy, the BF511 helps both clinicians and patients understand how body composition is shifting over time and where lifestyle interventions are most needed.

Used together, these devices provide a more complete picture of cardiovascular risk than either could offer alone. Blood pressure and heart rhythm data from the M4 Connect AFib, combined with body composition insights from the BF511, equip women and their healthcare teams with the information needed for early detection, targeted lifestyle adjustments, and better long-term heart health outcomes.

Conclusion

Menopause is a defining moment in women's cardiovascular health. The hormonal, metabolic, and body composition changes that accompany this transition create a cluster of risk factors that demand proactive clinical attention. By identifying risk early and monitoring key indicators consistently, healthcare professionals can make a meaningful difference in long-term outcomes for their patients.

Technology plays an important role in making this monitoring practical and patient-centred. OMRON's M4 Connect AFib and BF511 together support a data-driven approach to cardiovascular risk management, empowering women to navigate the menopausal transition with greater awareness and confidence in their heart health.

This content has been reviewed and approved by a cross-functional team at Omron Healthcare Europe to ensure the accuracy of the information provided. Approval Code: OHEAPP-1130